Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
21
10
2021
accepted:
04
05
2022
revised:
04
04
2022
pubmed:
24
5
2022
medline:
19
8
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients eligible for early-phase clinical trials. In this study the feasibility of whole-genome sequencing (WGS) as a one-test-for-all for guided inclusion in early-phase trials was investigated. Phase I Molecular Tumor Board (MTB) at the Erasmus MC Cancer Institute reviewed patients with advanced cancer without standard-of-care treatment (SOC) options for a 'fresh-frozen' (FF) tumour biopsy for WGS based on clinical-pathological features. Clinical grade WGS was performed by Hartwig Medical Foundation. MTB matched the patient with a trial, if available. From September 2019-March 2021, 31 patients with highly diverse tumour types underwent a tumour biopsy for WGS. The median turnaround time (TAT) was 15 days [10-42 days]. At least one actionable event was found in 84% of the patients (26/31). One-third of the patients (11/31) received matched experimental treatment. WGS on fresh FF biopsies is a feasible tool for the selection of personalised experimental therapy in patients with advanced cancer without SOC options. WGS is now possible in an acceptable TAT and thus could fulfil the role of a universal genomic pre-screening test.
Sections du résumé
BACKGROUND
Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients eligible for early-phase clinical trials. In this study the feasibility of whole-genome sequencing (WGS) as a one-test-for-all for guided inclusion in early-phase trials was investigated.
METHODS
Phase I Molecular Tumor Board (MTB) at the Erasmus MC Cancer Institute reviewed patients with advanced cancer without standard-of-care treatment (SOC) options for a 'fresh-frozen' (FF) tumour biopsy for WGS based on clinical-pathological features. Clinical grade WGS was performed by Hartwig Medical Foundation. MTB matched the patient with a trial, if available.
RESULTS
From September 2019-March 2021, 31 patients with highly diverse tumour types underwent a tumour biopsy for WGS. The median turnaround time (TAT) was 15 days [10-42 days]. At least one actionable event was found in 84% of the patients (26/31). One-third of the patients (11/31) received matched experimental treatment.
CONCLUSIONS
WGS on fresh FF biopsies is a feasible tool for the selection of personalised experimental therapy in patients with advanced cancer without SOC options. WGS is now possible in an acceptable TAT and thus could fulfil the role of a universal genomic pre-screening test.
Identifiants
pubmed: 35606463
doi: 10.1038/s41416-022-01841-3
pii: 10.1038/s41416-022-01841-3
pmc: PMC9381598
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-783Informations de copyright
© 2022. The Author(s).
Références
Bui NQ, Kummar S. Evolution of early phase clinical trials in oncology. J Mol Med. 2018;96:31–8.
doi: 10.1007/s00109-017-1612-7
Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magné N, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol. 2008;19:787–92.
doi: 10.1093/annonc/mdm548
Kimmelman J. Is participation in cancer phase I trials really therapeutic? J Clin Oncol. 2017;35:135–8.
doi: 10.1200/JCO.2016.67.9902
Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015;107:1–11.
doi: 10.1093/jnci/djv253
Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33:3817–25.
doi: 10.1200/JCO.2015.61.5997
Nelson AC, Yohe SL. Cancer whole-genome sequencing: the quest for comprehensive genomic profiling in routine oncology care. J Mol Diagn. 2021;23:784–7.
doi: 10.1016/j.jmoldx.2021.05.004
Yi K, Ju YS. Patterns and mechanisms of structural variations in human cancer. Exp Mol Med. 2018;50:98.
doi: 10.1038/s12276-018-0112-3
Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–62.
doi: 10.1016/j.celrep.2016.12.019
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–e51.
doi: 10.1016/S1470-2045(16)30406-5
Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer. Eur J Cancer. 2019;106:144–59.
doi: 10.1016/j.ejca.2018.11.002
Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970–7.
doi: 10.1158/1078-0432.CCR-19-1040
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346–58.
doi: 10.1038/s41590-020-0769-3
Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens MC, Dubbink HJ, et al. Clinical validation of whole genome sequencing for cancer diagnostics. J Mol Diagn. 2021;23:816–33.
doi: 10.1016/j.jmoldx.2021.04.011
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
doi: 10.1038/nature12477
Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, et al. Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer. 2012;118:1422–8.
doi: 10.1002/cncr.26413
Sanger Institute. COSMIC v92, released 27-AUG-20. 2020. https://cancer.sanger.ac.uk/cosmic .
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101.
doi: 10.1038/s41586-020-1943-3
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127–31.
doi: 10.1038/s41586-019-1600-x
Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, et al. Copenhagen prospective personalized oncology (CoPPO)—clinical utility of using molecular profiling to select patients to phase I trials. Clin Cancer Res. 2019;25:1239–47.
doi: 10.1158/1078-0432.CCR-18-1780
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25:744–50.
doi: 10.1038/s41591-019-0407-5
Tsimberidou A-M, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019;12:145.
doi: 10.1186/s13045-019-0835-1
Soldatos TG, Kaduthanam S, Jackson DB. Precision Oncology-The Quest for Evidence. J Person Med. 2019;9:1–17.
doi: 10.3390/jpm9030043
Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70:125–37.
doi: 10.3322/caac.21600
Tannock IF, Hickman JA. Molecular screening to select therapy for advanced cancer? Ann Oncol. 2019;30:661–3.
doi: 10.1093/annonc/mdz088
Dittrich C. Basket trials: from tumour gnostic to tumour agnostic drug development. Cancer Treat Rev. 2020;90:102082.
doi: 10.1016/j.ctrv.2020.102082
Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.
doi: 10.1186/s40425-018-0479-7
Lei JT, Zhang B. Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer. 2021;125:1–3.
doi: 10.1038/s41416-021-01346-5
Simons M, Van De Ven M, Coupé V, Joore M, Ijzerman M, Koffijberg E, et al. Early technology assessment of using whole genome sequencing in personalized oncology. Expert Rev Pharmacoecon Outcomes Res. 2021;21:343–51.
doi: 10.1080/14737167.2021.1917386
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, et al. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Med. 2021;13:87.
doi: 10.1186/s13073-021-00897-9
Riedl JM, Hasenleithner SO, Pregartner G, Scheipner L, Posch F, Groller K, et al. Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Ther Adv Med Oncol. 2021;13:1758835920987658.
doi: 10.1177/1758835920987658
Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, et al. Implementation and use of whole exome sequencing for metastatic solid cancer. EBioMedicine. 2020;51:102624.
doi: 10.1016/j.ebiom.2019.102624
Keith TF, Robert JG, Alice PC, Shuli L, Lisa MM, David P, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020;38:3883–94.
doi: 10.1200/JCO.19.03010
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8.
doi: 10.1038/s41591-019-0424-4
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25:738–43.
doi: 10.1038/s41591-019-0380-z
Tredan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardiere A, Fayette J, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol. 2019;30:757–65.
doi: 10.1093/annonc/mdz080
Rouven H, Anna-Lena G, Ralph F, Rainer C, Julius W, Patrick M, et al. Personalized clinical decision making through implementation of a molecular tumor board: a German Single-Center Experience. JCO Precision Oncol. 2018;2:1–16.
Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7:586–95.
doi: 10.1158/2159-8290.CD-16-1396
Cousin S, Grellety T, Toulmonde M, Auzanneau C, Khalifa E, Laizet Yh, et al. Clinical impact of extensive molecular profiling in advanced cancer patients. J Hematol Oncol. 2017;10:45.
doi: 10.1186/s13045-017-0411-5